Mobile

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with the addition of a licensed drug (Glimepiride) in patients with Type 2 Diabetes

Update Il y a 4 ans
Reference: EUCTR2012-002309-23

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

After 54 weeks, to assess the A1C-lowering efficacy of MK-3102 compared to glimepiride. To assess the safety and tolerability of MK-3102.

Inclusion criteria

  • Type 2 diabetes mellitus

Links